Availability and affordability of anti-VEGF biosimilars for the treatment of age-related macular degeneration and diabetic macular oedema in Sri Lanka
Community Eye Health Journal · 29.01.2025 · 37 (125)
DOI: 10.56920/cehj.836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Community Eye Health Journal, online erschienen am 29.01.2025. Verfasst von Mapa Prabhath Piyasena und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Piyasena, M. P., & Dhanapala, M. (2025). Availability and affordability of anti-VEGF biosimilars for the treatment of age-related macular degeneration and diabetic macular oedema in Sri Lanka. Community Eye Health Journal, 37(125). https://doi.org/10.56920/cehj.836
Vancouver
Piyasena MP, Dhanapala M. Availability and affordability of anti-VEGF biosimilars for the treatment of age-related macular degeneration and diabetic macular oedema in Sri Lanka. Community Eye Health Journal. 2025;37(125). doi:10.56920/cehj.836
BibTeX
@article{Piyasena2025,
author = {Piyasena, Mapa Prabhath and Dhanapala, Mangala},
title = {Availability and affordability of anti-VEGF biosimilars for the treatment of age-related macular degeneration and diabetic macular oedema in Sri Lanka},
journal = {Community Eye Health Journal},
year = {2025},
volume = {37},
number = {125},
doi = {10.56920/cehj.836}
}
EUVIMED